# A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia

> **NCT00060502** · PHASE2 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 73 (actual)

## Conditions studied

- Cachexia
- Pancreatic Neoplasms

## Interventions

- **DRUG:** Infliximab; Gemcitabine

## Key facts

- **NCT ID:** NCT00060502
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060502, "A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00060502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*